Study Type: POE Purpose: Does menopausal hormone therapy with either estrogen alone versus estrogen + progestin reduce the 1 year incidence and symptom severity of urinary incontinence (stress, urge and mixed)? Study Duration: 1-year follow-up of the planned 9-year study (was stopped early as published) Trial Design: This study compare the two arms of the WHI trial -estrogen only arm and estrogen + progestin arm, randomized-controlled, primary prevention trial, multicenter (40 US centers), intention-to-treat, those on hormone therapy were washout before enrollment, those with severe symptoms were excluded, also all patients went through a placebo run-in to assess adherence. Urinary symptoms were self-reported Drug: 0.625 conjugated equine estrogen vs placebo arm or 0.625 conjugated equine estrogen + medroxyprogesterone 2.5 mg vs placebo arm (2 separate studies are compared). Patients: n = 27,347 (10,739 patients in estrogen only arm and 16,608 in combination arm), mean age 63 +/-7 yrs (~45% 60-69, 24% 70-79), 75% white, ~52% were never user's of HRT; 53% HRT user's have been using < 5 yrs, 28% have used > 10 yrs; BMI = 30; BP = 130/77; 52% never smoked; 91% had one or more pregnancies; 67% had first child between 20 and 29 yrs of age, 43% had hysterectomy between the ages of 40-49 Inclusion: age 50 to 79; postmenopausal, hysterectomy, staying in residence for 3 more yrs Exclusion: competing risks with a predicted survival of < 3 yrs; safety (breast cancer, or within 3 yrs, low HCT or platelets); alcoholism; dementia; those with transportation problems Outcome Events: Change in urinary symptoms on survey -self-reported
1.
Are 
Will the results help me?
• The study results are weakened due to the fact that the initial assessment of symptoms was self-reported.
• The older the patient, the more likely incontinence when using hormones, especially in those > 60 yrs.
• The longer the use, the more likely incontinence, longer than 5 yrs.
• The general characteristics of the incontinence worsened on hormone therapy (i.e., amount of urine, frequency)
Conclusion:
Hormone therapy does not protect against any form of urinary incontinence, In fact, for every 1000 patients treated with Prempro®, 72 would complain of stress incontinence. Those taking Premain® and no progestin are more likely to have urinary incontinence symptoms than those taking the combination hormone.
